
Submission Confirmation

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Tue, Aug 18, 2020 at 6:20 AM

Dear Alfinda Novi Kristanti,

Your submission entitled **SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION** (Manuscript Number: JAPS-2020-08-901) has been received by **Journal of Applied Pharmaceutical Science**.

You could follow status of your manuscript by login to your author account at www.ejmanager.com.

Please note that peer-review process may take 60 day's time, the emails related to status update will not be answered before review period.

Thank you for submitting your work to our journal.

Best regards,

Editor
Journal of Applied Pharmaceutical Science
<http://japsonline.com/index.php>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Article Revision Letter for Authors - (JAPS-2020-08-901)

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Wed, Sep 2, 2020 at 7:14 PM

Dear Alfinda Novi Kristanti,

Your manuscript entitled "SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION" (Ms.Nr. JAPS-2020-08-901) was reviewed by referees. As initial decision, your manuscript was found interesting but some revisions have to be made before it can reach a publishable value. Please answer all the comments below point-by-point in an accompanying response letter to your revised submission.

You should send your revised manuscript via our online system available at <http://my.ejmanager.com/japs/>

Please add journals@ejmanager.com in your contact list to ensure the safe delivery of our emails to your inbox.

Sincerely yours,

Editorial Office
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>

COMMENTS for Authors:

=> Reviewer # 1

The Authors describe the synthesis of a small library of styrylchromones and study their anticancer activity both in vivo and in silico. It should be noted that some compounds are already known and have been studied precisely for their antitumor activity.

There are typographical errors:

Page 1, line 1: not "2-styrylchromone" but "Styrylchromone"

Page 2, line 20: not "0.33 gr" but "0.33 g"

Page 3, line 3: not "stiring" but "stirring"

Page 3, line 18: not "37o" but "37°"

Page 5, line 3: not ".Another" but ". Another"

Page 7, line 20: not "1,0 Hz); but "1,0 Hz, 1H);

Page 12, line 2: not "2-styrylchromone derivatives" but "2-Styrylchromone derivatives"

Table 2: not "Doksorubisin" but "Doxorubicin"

Major issues:

- There is no description of how the two compounds (4-methylcoumarine and 2-methylchromanone) are separated. Further, the melting point of 2-methylchromanone is missing.

- In the formulas, the order of the elements is C, H, halogen (Cl or Br) and O: for example, compound 4c is C₁₇H₁₁BrO₂ and not C₁₇H₁₁O₂Br.

-There are several errors in the H NMR data:

Compound 4a: one proton is missing

Compound 4e: the signals relating to the 2 OCH₃ groups are missing

Compound 4g: the signals relating to the 3 OCH₃ groups are missing

The compounds 4a-c and 4g are already known. It is necessary to report this information.

- In addition, the compounds have already been studied precisely for their antitumor activity. In this regard it is necessary to mention the two references:

Lin C, Lu P-J, Yang C-N, Hulme C, Shaw A.Y. Structure-activity relationship study of growth inhibitory 2-styrylchromones against carcinoma cells. *Med. Chem. Res.*, 2013, 22(5), 2385-2394

Momoi K, Sugita Y, Ishihara M, et al. Cytotoxic activity of styrylchromones against human tumor cell lines. *In vivo*, 2005, 19(1), 157-163.

- The value of percent inhibitions (Table 2) are obtained with a single experiment (poor scientific significance) or are the average value of several experiments. In the latter case, the standard deviation must be reported. In the first case, it is necessary to specify that the results are obtained with a single assay.

=> Reviewer # 2

The work is average but may be improved by the inclusion of the following suggestions.

1. English should be improved throughout the manuscript.
2. Quantitative information should be provided in the abstract.
3. The conclusion should be concise and to the points indicating the application of the work.
4. The novelty of the work should be established.

5. Write one paragraph in the introduction on cancer in general with citations of the following refs.
Polyhedron, 56, 134-143 (2013).; Current Cancer Drug Targets, 11, 131-134 (2011).; Curr. Drug Target, 16: 711-734 (2015).; Med. Chem. Res., 22:1386-1398 (2013).; Future Med. Chem., 5: 135-146 (2013).; Cur. Pharm. Anal., 1, 109-125 (2005).; Med. Chem. Commun., 8: 1742-1773 (2017).

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Revised Article Submission

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Tue, Sep 15, 2020 at 9:44 PM

Dear Alfinda Novi Kristanti,

Your REVISED ARTICLE entitled **SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION** (Mns No:JAPS-2020-08-901) has been received by **Journal of Applied Pharmaceutical Science**.

You could follow the status of your manuscript by login to your author account at www.ejmanager.com.

Thank you for submitting REVISED version of your article.

Best regards,

Editor
Journal of Applied Pharmaceutical Science
<http://japsonline.com/index.php>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Article Revision Letter for Authors - (JAPS-2020-08-901)

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Wed, Oct 7, 2020 at 3:58 PM

Dear Alfinda Novi Kristanti,

The revisions for your manuscript titled -SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION- and manuscript number (JAPS-2020-08-901) was reviewed by Editorial Board of Journal of Applied Pharmaceutical Science and decided that the following revisions should be done. Please answer all the comments below, in your answer letter.

You should send your revised manuscript by journal Submit Article page.

Sincerely yours,

Editor
Journal of Applied Pharmaceutical Science
paraszee05@gmail.com
<http://my.ejmanager.com/japs>
<http://japsonline.com/index.php>

COMMENTS for Authors:

=> Reviewer # 1 --- 2. Review

In this revised form, the manuscript does not highlight major issues.

There are only three typographical errors:

Page 4, line 15: not \"elucidated\" but \"eluited\"

Page 8, line 17: not \"2-metylchromone\" but \"2-methylchromone\"

Page 9, line 19: not \"(E)-2-(4-bromorstiry)-4H-chromen-4-one\" but \"(E)-2-(4-bromostiry)-4H-chromen-4-one\"

In this revised version, the paper can be considered for the publication.

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Revised Article Submission

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Wed, Oct 7, 2020 at 5:08 PM

Dear Alfinda Novi Kristanti,

Your REVISED ARTICLE entitled **SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION** (Mns No:JAPS-2020-08-901) has been received by **Journal of Applied Pharmaceutical Science**.

You could follow the status of your manuscript by login to your author account at www.ejmanager.com.

Thank you for submitting REVISED version of your article.

Best regards,

Editor
Journal of Applied Pharmaceutical Science
<http://japsonline.com/index.php>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Decision Letter to Authors - Acceptance - (JAPS-2020-08-901)

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Wed, Oct 21, 2020 at 2:53 PM

Dear Alfinda Novi Kristanti,

I am pleased to inform you that your manuscript titled "SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION" (Manuscript Number: JAPS-2020-08-901) is accepted for publication in the Journal of Applied Pharmaceutical Science. You are required to submit article processing charges within next three days of receiving this mail through Banking/Paypal. Payment details will be sent in a separate email.

We encourage the authors to host the accepted version of the article to their research gate/google scholar. You could check your possible publication date at your author page.

You may login to your author account page, and visit accepted articles section in order to get official/formal acceptance letter as PDF.

I would like to remind that you could send your future manuscripts to Journal of Applied Pharmaceutical Science.

Sincerely yours,

Paras Sharma
Associate Editor
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Notification for Status Change of your Article

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Wed, Oct 21, 2020 at 2:54 PM

Dear Alfinda Novi Kristanti,

As declared in "Instructions for Authors", you are required to pay the article processing charges \$357 [including 14 additional pages + language editing and transaction charges] for your article accepted for publication in Journal of Applied Pharmaceutical Science. Although the currency is US Dollar, you may change the currency during the payment process.

In order to make payment, login to your account at <http://my.ejmanager.com/japs/> ---> open Articles waiting for Payment ---> find Articles waiting for Payment and make your payment by your credit/debit card or your paypal account.

Best Regards

Editor
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://my.ejmanager.com/japs>
<http://japsonline.com/index.php>

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Read Proof of Your Article at eJManager - (JAPS-2020-08-901)

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Fri, Nov 6, 2020 at 12:29 PM

Dear Alfinda Novi Kristanti,

Your article "SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION" is almost ready for publication at Journal of Applied Pharmaceutical Science. But before publication your final check will be highly appreciated. For this reason, the galley proof of your accepted article was uploaded to your author homepage.

Please note 'The changes those affects the scientific outcome, methods and overall findings of article are not allowed at this stage'.

Please log in, download the proof and check/read it carefully for any mistake or typographical error(s); then submit your corrections (if exist) within 48 hours. Please also consider that no changes can be made in your article after this step.

Please read the guidelines given below for submission of corrections for galley proof (if any).

Editor
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>

Guidelines for sending the corrections for galley proof;

1. The changes those affects the scientific outcome, methods and overall findings of article are not allowed at this stage.
2. Write page number, Major/minor heading and line number.
3. Write the uncorrected text, corrections required and corrected text.
4. Do not send unnecessary corrections.

For example;

Correction: 1
Page no 1
Major heading: Material and Methods
Minor Heading: Plant material
Line no: 4
Uncorrected text: '.....leaves of the plant was collected...'
Corrected text: '.....leaves of the plant were collected...'

Correction: 2
Page no 1
Line no: 4
Major heading: Material and Methods
Minor Heading: Animal
Uncorrected text: '.....Animals were keep at...'
Corrected text: '.....Animals were kept at ...'

[Link: <http://my.ejmanager.com/japs/>]

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>

Read Proof of Your Article at eJManager - (JAPS-2020-08-901)

1 message

noreply@ejmanager.com <noreply@ejmanager.com>
Reply-To: "noreply@ejmanager.com" <noreply@ejmanager.com>
To: alfinda-n-k@fst.unair.ac.id

Tue, Nov 10, 2020 at 11:21 PM

Dear Alfinda Novi Kristanti,

Your article "SYNTHESIS OF 2-STYRYLCHROMONES, IN VITRO AND IN SILICO ANTICANCER ACTIVITY EVALUATION" is almost ready for publication at Journal of Applied Pharmaceutical Science. But before publication your final check will be highly appreciated. For this reason, the galley proof of your accepted article was uploaded to your author homepage.

Please note 'The changes those affects the scientific outcome, methods and overall findings of article are not allowed at this stage'.

Please log in, download the proof and check/read it carefully for any mistake or typographical error(s); then submit your corrections (if exist) within 48 hours. Please also consider that no changes can be made in your article after this step.

Please read the guidelines given below for submission of corrections for galley proof (if any).

Editor
Journal of Applied Pharmaceutical Science
editor@japsonline.com
<http://japsonline.com/index.php>

Guidelines for sending the corrections for galley proof;

1. The changes those affects the scientific outcome, methods and overall findings of article are not allowed at this stage.
2. Write page number, Major/minor heading and line number.
3. Write the uncorrected text, corrections required and corrected text.
4. Do not send unnecessary corrections.

For example;

Correction: 1
Page no 1
Major heading: Material and Methods
Minor Heading: Plant material
Line no: 4
Uncorrected text: '.....leaves of the plant was collected...'
Corrected text: '.....leaves of the plant were collected...'

Correction: 2
Page no 1
Line no: 4
Major heading: Material and Methods
Minor Heading: Animal
Uncorrected text: '.....Animals were keep at...'
Corrected text: '.....Animals were kept at ...'

[Link: <http://my.ejmanager.com/japs/>]

IMPORTANT: USE JOURNAL CONTACT EMAIL for your messages. Do not answer to this email. It is not checked for messages

<http://www.ejmanager.com>
